Recent articles on developments and controversies in the treatment of chronic lymphocytic leukemia include the following features from The ASCO Post, which are also available at www.ascopost.com:
- “Recent FDA Approvals Foster Growing Treatment Armamentarium for Chronic Lymphocytic Leukemia and Rare B-Cell Lymphomas,” August 15, 2014
- “Ibrutinib Surpasses Ofatumumab as Second-Line Treatment of Chronic Lymphocytic Leukemia,” by Alice Goodman, June 25, 2014
- “Looking Ahead in Treating Chronic Lymphocytic Leukemia,” by Caroline Helwick, June 10, 2014
- “Ibrutinib for Previously Treated Chronic Lymphocytic Leukemia,” by Matthew Stenger, March 15, 2014
- “Encouraging Early Results With Novel Agents in CLL,” by Alice Goodman, March 1, 2014
- “First-Line Obinutuzumab/Chlorambucil Improves Outcomes Over Rituximab/Chlorambucil in Older CLL Patients With Comorbidities,” by Alice Goodman, March 1, 2014
- “Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia,” by Matthew Stenger,
December 1, 2013 - “High Rate of Durable Remissions With Ibrutinib in Patients With Relapsed Chronic Lymphocytic
Leukemia,” by Matthew Stenger, August 15, 2013 - “Potent Activity Shown for First-in-Class PI3K-delta Inhibitor in Chronic Lymphocytic Leukemia,” by Caroline Helwick, June 10, 2013
- “Ibrutinib CLL Trial: Where Is the Equipoise?” by Susan O’Brien, MD, May 1, 2013
- “The Ethical Imperative of Clinical Equipoise,” by Steven J. Schuster, MD, May 1, 2013
- “A Promising New Agent’s Road to Approval in CLL Raises Questions, Stirs Controversy,” by Ronald Piana, May 1, 2013 ■
